Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509]

  • Awaiting development
  • GID-TA11658
  • Expected publication date: TBC

Suggested remit: To appraise the clinical and cost effectiveness of Trastuzumab with chemotherapy within its marketing authorisation for treating breast cancer